Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

5.4K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
5.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An unusual case of short tandem repeat analysis with foreign peaks due to granulocyte transfusion.

Transfusion·2026
Same author

Therapeutic Plateletpheresis for Thrombocytosis: Critical Analytic Reviews and Original Multicenter Experience.

Transfusion medicine reviews·2026
Same author

Developing a Protocol for Therapeutic Plasma Exchange in Tandem With Continuous Renal Replacement Therapy (CRRT) and ExtraCorporeal Membrane Oxygenation (ECMO) in Pediatric Patients.

Journal of clinical apheresis·2025
Same author

Standardization of Blood Product Orders Improves Patient Safety in Pediatric Transfusion Medicine: A Collaborative Project.

Archives of pathology & laboratory medicine·2025
Same author

Parent perceptions of emergent blood transfusion in children.

Transfusion·2023
Same author

Multi-institutional experience with COVID-19 convalescent plasma in children.

Transfusion·2023
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Related Experiment Video

Updated: Apr 3, 2026

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.7K

Optimizing platelet transfusions.

Kyle Annen1, Jordan E Olson

  • 1aBlood Center of Wisconsin, Medical Sciences and Blood Research Institutes, Milwaukee, Wisconsin bHeartland Blood Center, Aurora, Illinois cDepartment of Pathology, McGaw Medical Center of Northwestern University, Chicago, Illinois dDepartment of Laboratory Medicine, Geisinger Health System, Danville, Pennsylvania, USA.

Current Opinion in Hematology
|September 22, 2015
PubMed
Summary
This summary is machine-generated.

Platelet transfusions are evolving, with prophylactic transfusions proving superior for chemotherapy patients. Current practices for immune refractoriness and antiplatelet reversal lack definitive evidence, prompting a reevaluation of platelet therapy.

More Related Videos

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

10.1K
Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

14.2K

Related Experiment Videos

Last Updated: Apr 3, 2026

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.7K
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

10.1K
Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

14.2K

Area of Science:

  • Hematology
  • Transfusion Medicine

Background:

  • Platelet transfusion is a critical but complex medical procedure.
  • Concerns regarding bacterial contamination and suboptimal evidence for transfusion thresholds drive research.
  • Recent studies challenge established platelet transfusion policies and practices.

Purpose of the Study:

  • To review recent studies and literature addressing current challenges in platelet transfusion.
  • To highlight innovative approaches to platelet transfusion criteria and policies.
  • To examine the evidence base for various platelet transfusion scenarios.

Main Methods:

  • Review of recent randomized controlled trials (RCTs) and observational studies.
  • Analysis of literature concerning prophylactic versus therapeutic platelet transfusions.
  • Evaluation of evidence for human leukocyte antigen (HLA)-matched and cross-matched platelets.
  • Assessment of data on platelet transfusion for antiplatelet medication reversal.
  • Consideration of ABO plasma-incompatible transfusions and product availability.

Main Results:

  • Prophylactic platelet transfusions are more effective than therapeutic transfusions for preventing bleeding in chemotherapy and hematopoietic stem cell transplant patients.
  • Human leukocyte antigen-matched or cross-matched platelets show limited effectiveness in treating immune refractoriness.
  • Evidence supporting the benefit of platelet transfusion for emergent reversal of antiplatelet medications is inconclusive.
  • ABO plasma-incompatible platelet transfusions carry a risk of hemolysis; low-titer products are recommended but not widely available.

Conclusions:

  • Platelet transfusion practices are undergoing significant scrutiny and reevaluation.
  • The development of improved therapies and guidelines will likely lead to changes in platelet therapy.
  • Further research is needed to clarify optimal strategies for various clinical situations.